Literature DB >> 2573596

Cardioprotective and antiarrhythmic effects of beta-blockers, propranolol, bisoprolol, and nipradilol in a canine model of regional ischemia.

T Ogawa1, N Hieda, S Sugiyama, T Ito, T Satake, T Ozawa.   

Abstract

Cardioprotective and antiarrhythmic effects of three beta-blockers with different pharmacological properties were investigated in 33 anesthetized dogs with a 2-h coronary occlusion. Dogs were divided into 4 groups and received physiological saline or one of the following drugs using a 10-min infusion at 25 min before the occlusion: saline or control (n = 12), propranolol (0.3 mg/kg, n = 7), bisoprolol (0.05 mg/kg, n = 7), and nipradilol (0.2 mg/kg, n = 7) groups. Blood pressure did not significantly differ among the 4 experimental groups throughout the entire observation period. On the contrary, the postocclusion change (fall) in heart rate from the preocclusion value was significantly (P less than 0.05-0.01) greater in the drug-treated groups than in the control group. Each of the beta-blockers effectively prevented the development of ventricular arrhythmias associated with the 2-h coronary occlusion. In terms of assessing a cardioprotective effect, the respiratory control index and rate of oxygen consumption in State III in mitochondria, and lysosomal enzyme activities (N-acetyl-beta-glucosaminidase or beta-glucuronidase) in myocardial tissues, all prepared from both ischemic and non-ischemic areas, were measured using the respective, established methods. The 2-h coronary occlusion induced a mitochondrial dysfunction and leakage of lysosomal enzymes in the control group, whereas each beta-blocker significantly (P less than 0.05-0.01) protected mitochondria against ischemia and prevented the lysosomal enzyme leakage. The results indicate that the antiarrhythmic effects of beta-blockers on ischemic myocardium are, at least in part, due to their cardioprotective action, and these effects appear to be unrelated to the ancillary pharmacological properties of these drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573596     DOI: 10.1007/BF02058353

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  38 in total

1.  A new technique for isolation of particulate lysosomal activity from canine and rat myocardium.

Authors:  R C Ruth; F F Kennett; W B Weglicki
Journal:  J Mol Cell Cardiol       Date:  1978-08       Impact factor: 5.000

2.  Protection of the ischemic myocardium. Introductory remarks.

Authors:  E Braunwald
Journal:  Circulation       Date:  1976-03       Impact factor: 29.690

3.  Differing mechanisms for ventricular vulnerability during coronary artery occlusion and release.

Authors:  R Corbalan; R L Verrier; B Lown
Journal:  Am Heart J       Date:  1976-08       Impact factor: 4.749

4.  Lysosomal responses of fetal mouse hearts recovering from anoxia and substrate depletion.

Authors:  R M Ridout; K Wildenthal; R S Decker
Journal:  J Mol Cell Cardiol       Date:  1986-08       Impact factor: 5.000

5.  Prostaglandin I2 analogue and propranolol prevent ischaemia induced mitochondrial dysfunction through the stabilisation of lysosomal membranes.

Authors:  N Hieda; Y Toki; S Sugiyama; T Ito; T Satake; T Ozawa
Journal:  Cardiovasc Res       Date:  1988-03       Impact factor: 10.787

6.  Characterization of [3H](+/-)carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung.

Authors:  A S Manalan; H R Besch; A M Watanabe
Journal:  Circ Res       Date:  1981-08       Impact factor: 17.367

7.  A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction.

Authors:  W O'Neill; G C Timmis; P D Bourdillon; P Lai; V Ganghadarhan; J Walton; R Ramos; N Laufer; S Gordon; M A Schork
Journal:  N Engl J Med       Date:  1986-03-27       Impact factor: 91.245

8.  Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival.

Authors:  M L Simoons; P W Serruys; M van den Brand; J Res; F W Verheugt; X H Krauss; W J Remme; F Bär; C de Zwaan; A van der Laarse
Journal:  J Am Coll Cardiol       Date:  1986-04       Impact factor: 24.094

9.  Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension.

Authors:  L Weiner; G Frithz
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

10.  High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol.

Authors:  G Haeusler; H J Schliep; P Schelling; K H Becker; M Klockow; K O Minck; H J Enenkel; E Schulze; R Bergmann; C J Schmitges
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

View more
  1 in total

1.  Nipradilol, a new beta-adrenergic blocker, reduces left ventricular remodeling following myocardial infarction in spontaneously hypertensive rats.

Authors:  H Sonoki; M Nakamura; A Takeshita
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.